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Hepcidin is regulated by promoter-associated
histone acetylation and HDAC3
Sant-Rayn Pasricha 1,2, Pei Jin Lim1, Tiago L. Duarte 3, Carla Casu4, Dorenda Oosterhuis5,
Katarzyna Mleczko-Sanecka6,7, Maria Suciu8, Ana Rita Da Silva6, Kinda Al-Hourani1, João Arezes1,
Kirsty McHugh9, Sarah Gooding1, Joe N. Frost1, Katherine Wray1, Ana Santos3, Graça Porto3,10,
Emmanouela Repapi11, Nicki Gray11, Simon J. Draper 9, Neil Ashley8, Elizabeth Soilleux12,13, Peter Olinga5,
Martina U. Muckenthaler6, Jim R. Hughes 8, Stefano Rivella4, Thomas A. Milne 8, Andrew E. Armitage1
& Hal Drakesmith1
Hepcidin regulates systemic iron homeostasis. Suppression of hepcidin expression occurs
physiologically in iron deficiency and increased erythropoiesis but is pathologic in thalassemia
and hemochromatosis. Here we show that epigenetic events govern hepcidin expression.
Erythropoiesis and iron deficiency suppress hepcidin via erythroferrone-dependent and
-independent mechanisms, respectively, in vivo, but both involve reversible loss of H3K9ac
and H3K4me3 at the hepcidin locus. In vitro, pan-histone deacetylase inhibition elevates
hepcidin expression, and in vivo maintains H3K9ac at hepcidin-associated chromatin
and abrogates hepcidin suppression by erythropoietin, iron deficiency, thalassemia, and
hemochromatosis. Histone deacetylase 3 and its cofactor NCOR1 regulate hepcidin; histone
deacetylase 3 binds chromatin at the hepcidin locus, and histone deacetylase 3 knockdown
counteracts hepcidin suppression induced either by erythroferrone or by inhibiting bone
morphogenetic protein signaling. In iron deficient mice, the histone deacetylase 3 inhibitor
RGFP966 increases hepcidin, and RNA sequencing confirms hepcidin is one of the genes
most differentially regulated by this drug in vivo. We conclude that suppression of hepcidin
expression involves epigenetic regulation by histone deacetylase 3.
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The liver-expressed peptide hormone hepcidin, encoded byHAMP in humans (Hamp1 in mice), controls systemic ironlevels by inhibiting intestinal iron absorption and
iron recycling1. Expression of hepcidin is regulated by iron
status, erythropoietic drive, hypoxia, and inflammation2.
Iron accumulation in the liver stimulates bone morphogenetic
protein-6 (BMP6) signaling, which enables homeostatic responses
to iron loading by inducing hepcidin expression via SMAD
transcription factors3–5. Inflammatory cytokines such as
interleukin-6 elevate hepcidin levels through activation of
STAT36.
Hepcidin levels are suppressed in patients with iron deficiency
(ID) and in patients with increased erythropoiesis (e.g.,
with thalassemia). Increased erythropoietic drive suppresses
hepcidin7 at least partly via the erythroblast-secreted
hormone erythroferrone (encoded by the gene Fam132b)8,
which is considered to largely account for hepcidin suppression in
stress erythropoiesis and thalassemia8, 9. Suppression of hepcidin
in ID is thought to occur due to diminished BMP
signaling, achieved both through decreased iron-dependent
BMP6 expression10, and following cleavage of the BMP6
co-receptor hemojuvelin via TMPRSS611. However, a role for
erythroferrone in suppression of hepcidin in ID has also been
proposed12 although not confirmed. Hypoxia may also mediate
hepcidin suppression, either indirectly via erythropoiesis13 or via
secreted factors such as PDGF-BB14. Defects in the pathways that
regulate hepcidin produce disease: relative reductions in hepcidin
underlie most forms of hereditary hemochromatosis15, ineffective
erythropoiesis suppresses hepcidin contributing to iron loading
in thalassemia16, 17 and inflammation elevates hepcidin leading
to anemia of inflammation18. Restoring hepcidin levels in
hemochromatosis or thalassemia19, 20 or reducing it in anemia of
inflammation21 are major therapeutic ambitions.
Plasma hepcidin levels appear chiefly regulated by
transcriptional changes in hepatic hepcidin gene expression.
Although progress has been made in understanding hepatic
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Fig. 1 Effects of erythropoietin and iron deficiency in vivo. Effects of (1) 3 days erythropoietin (Epo) 200 IU i.p. administration and (2) 2 or 3 –weeks of iron-
deficient (2–6 ppm) diet in C57Bl/6 mice, on a hepatic Hamp1 gene expression, b hemoglobin concentration, c bone marrow Fam132b gene expression, d
bone marrow glycophorin C, e spleen weight, f hepatic Id1 gene expression, g hepatic Smad7 gene expression. Effects of 2 weeks iron-deficient diet on h renal
Epo gene expression, and i serum iron. (Epo experiment n= 13 per group, 6-week-old males; iron deficiency (ID) experiments n= 5 per group, 4-week-old
males at commencement of experimental diet). Student’s t-test. Data are means± s.e.m. *P≤ 0.05; **P≤ 0.01; ***P≤ 0.001; ****P≤ 0.0001; NS, P> 0.05
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hepcidin regulation, critical events at the hepcidin gene locus that
control changes in expression remain poorly defined. In general,
post-translational histone modifications (e.g., acetylation
and methylation) associate with, and may directly mediate,
transcriptional status22. Histone deacetylase (HDAC) inhibitors
are compounds which inhibit HDACs, thus generally increasing
histone acetylation. Treatment of hepatic cells in vitro
with HDAC inhibitors has been observed to raise hepcidin
expression23–25, and SMAD4 (the canonical hepcidin regulatory
transcription factor) overexpression and BMP treatment raised
H3K4me3 and H3K9ac at the hepcidin promoter in vitro26.
We sought to extend these insights to discover how
histone modifications at the hepcidin locus mediate regulation of
hepcidin expression in response to physiologic stimuli in vivo,
and to identify specific epigenetic regulators of hepcidin. Here,
we report that histone activation marks are removed from the
hepcidin locus when hepcidin is physiologically suppressed,
that hepcidin expression can be rescued from physiologic
inhibition by HDAC inhibition, and that HDAC3 and its
cofactors regulate hepcidin expression.
Results
Erythropoiesis and ID suppress hepcidin via distinct paths. We
recapitulated scenarios of stress erythropoiesis and ID using two
experimental mouse models of hepcidin suppression—stimulated
erythropoiesis with recombinant human erythropoietin (Epo),
and induction of ID via a low-iron diet. Three days of Epo
treatment reduced liver Hamp1 ~30–fold, while 2 weeks low-iron
diet induced ~9-fold suppression of Hamp1 (Fig. 1a), although
these treatments have no effect on hemoglobin (Hb) concentra-
tions (Fig. 1b) or liver iron (Supplementary Fig. 1a). Indicative
of stimulated erythropoiesis, Epo increased bone marrow
Fam132b (~50-fold, Fig. 1c), Glyc (~1.7-fold, Fig. 1d), and
Tfrc (Supplementary Fig. 1b) expression, and spleen weights
approximately doubled (Fig. 1e). The disproportionate increase
in Fam132b compared with Glyc expression perhaps reflects the
direct effect of Epo receptor-mediated Jak-Stat signaling on the
erythroferrone locus8. In contrast, ID did not increase bone
marrow Fam132b expression, bone marrow Glyc, or spleen size
(Fig. 1c–e). ID mice had reduced liver expression of Bmp target
genes Id1 and Smad7, and after 3 weeks low-iron diet, Atoh8 and
Bmp6, consistent with sensing of lower iron levels10 and the
homeostatic response of hepcidin suppression occurring via
reduced Bmp signaling (Fig. 1f, g; Supplementary Fig. 1c, d); these
changes were not seen in mice administered Epo. ID in these
experiments was not associated with a significant increase in
kidney Epo messenger RNA (mRNA) (Fig. 1h). ID (Fig. 1i) but
not Epo treatment (Supplementary Fig. 4h) reduced serum iron.
Suppression of hepcidin by ID is erythroferrone-independent.
These findings indicate that our Epo treatment regime induced
hepatic hepcidin suppression but did not strongly perturb BMP
signaling, while ID induced hepcidin suppression but did not
affect erythroferrone expression. To establish whether hepcidin
suppression in ID was erythroferrone-independent, we induced
ID in Fam132b knockout mice using a low-iron diet for 3 weeks,
which decreased liver iron (Fig. 2a). Iron-deficient Fam132b
knockout mice had a similar degree of hepcidin suppression to
control mice (gene expression data Fig. 2b, fold change data
Supplementary Fig. 2a), associated with reduced Bmp6 expression
and BMP signaling (lower expression of Id1, Smad7, and Atoh8)
(raw expression data Fig. 2c–f, fold changes shown in
Supplementary Fig. 2a). These data indicate that suppression of
hepcidin by ID does not require erythroferrone. In contrast, and
as previously shown8, Fam132b knockout mice do not suppress
hepcidin following administration of Epo, showing the critical
role of this gene in suppression of hepcidin by erythropoiesis
(Supplementary Fig. 2b).
Epo and ID cause loss of Hamp1-associated H3K9ac and
H3K4me3. We next investigated whether hepcidin suppression
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Fig. 2 Effects of ID in Fam132b knockout mice. Effects of 3-week iron-deficient diet compared with control diet in 5-week-old wild-type and Fam132b
knockout mice, on a liver iron content, b hepatic Hamp1 mRNA expression, c hepatic Bmp6 mRNA expression, d hepatic Id1 mRNA expression, e hepatic
Smad7 mRNA expression, and f hepatic Atoh8 mRNA expression (WT mice, N= 4 per group. KO mice, N= 8 per group). Student’s t-test. Data are means
± s.e.m. *P≤ 0.05; **P≤ 0.01; ***P≤ 0.001; ****P≤ 0.0001; NS, P> 0.05
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was associated with epigenetic modifications at the Hamp1 locus.
In the basal state in wild-type mice subsisting on standard chow,
when Hamp1 is highly expressed, chromatin is open at the
hepcidin locus (characterized by a DNase hypersensitive peak at
the promoter) and activation-associated histone marks (H3K9ac,
H3K4me3) are present; in contrast, the repressive mark
H3K27me3 is absent (Fig. 3a). Chromatin immunoprecipitation
(ChIP)–quantitative PCR (qPCR) assays demonstrated erasure of
H3K9ac and H3K4me3 at the hepcidin locus after 3 days of Epo
treatment (Fig. 3b). Loss of RNA Polymerase II binding to the
hepcidin promoter and gene body was also observed (Fig. 3b),
confirming that hepcidin suppression is mediated by loss
of transcription initiation, rather than through inhibition
of transcription elongation or post-transcriptional mechanisms
(e.g., via mRNA stability or translational regulation). The lost
activation marks were not replaced by repressive marks
(H3K27me3) (Fig. 3b), suggesting that Polycomb repressive
complex 2 is not involved in repression of Hamp1; indeed,
6 weeks following 3 days of Epo treatment, Hamp1 expression
had returned to normal levels, accompanied by restoration of
H3K9ac and H3K4me3 at the Hamp1 promoter (Fig. 3c). In mice
receiving iron-deficient diets, hepcidin suppression was likewise
accompanied by erasure of activation-associated histone
marks (H3K9ac and H3K4me3) (Fig. 3d). In the human
hepatoma Huh7 cell line, upregulation of hepcidin expression
through the canonical BMP pathway increased H3K9ac at
the HAMP promoter, while suppression of HAMP mRNA
expression using a BMP receptor inhibitor (LDN193189) reduced
enrichment for this mark (Fig. 3e; Supplementary Fig. 2c).
These data indicate that loss of activation-associated histone
marks at the Hamp1 promoter is a common feature of hepcidin
transcriptional suppression caused by both erythropoiesis and
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mild ID, but importantly for a hormone mediating systemic iron
homeostasis, this suppression is reversible and does not result in
long-term gene “silencing”.
Histone deacetylase inhibition prevents Hamp1 suppression.
A gene’s histone acetylation profile results from the balance
between histone acetyl transferases (HATs) and HDACs27. We
next sought to examine whether histone deacetylation in the
context of hepcidin suppression could be prevented by co-
administration of an HDAC inhibitor, and whether this would
affect hepcidin gene expression. The pan-HDAC inhibitor
Panobinostat (PB) has an IC50 in the nM range for most
HDACs28. Mice co-administered 3 days each of Epo and PB 20
mg/kg/d was rescued from loss of H3K9ac at the Hamp1 locus,
while mice receiving PB alone displayed hyperacetylation
(Fig. 4a). Partial rescue of H3K4me3 was also observed, consistent
with a degree of co-dependence of these marks, perhaps mediated
by effects of p300-dependent histone acetylation on SET-
mediated H3K4 trimethylation29.
Rescue of histone deacetylation in mice co-treated with Epo
by PB was associated with increased hepcidin expression to
levels similar to control mice (Fig. 4b). Hyperacetylation of the
hepcidin promoter in mice treated with PB alone (compared with
control) was associated with an increase in Hamp1 expression
over control and Epo + PB-treated mice, indicating some residual
suppression of hepcidin caused by Epo in this latter group.
Inhibition of hepcidin suppression occurred even though bone
marrow Fam132b was still upregulated by Epo in the presence of
PB. Although PB reduced spleen weight in non-Epo-treated mice
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and ameliorated Epo-induced increases in spleen weight
(Supplementary Fig. 3a), the increased intermediate erythroblast
population (Ery II) seen in mice treated with Epo was
similar between PB-treated and untreated populations (Fig. 4c).
Intermediate erythroblasts strongly express Fam132b, and
Epo-mediated increased splenic Fam132b expression was not
affected by PB treatment (Supplementary Fig. 3b). PB was
characteristically associated with reduced platelets
(Supplementary Fig. 3c)30, but did not affect Hb or mouse
weight (Supplementary Fig. 3d, e). Although liver iron and Bmp6
expression were marginally increased in mice receiving Epo + PB
compared to Epo (Supplementary Fig. 3f, g), serum iron, which
influences liver Bmp signaling31, and expression of the Bmp
target genes Id1, Smad7, and Atoh8, was not increased (Fig. 3b;
Supplementary Fig. 3g, h).
When mice receiving a 2-week low-iron diet were co-treated
with PB 20 mg/kg for the final 7 days, they likewise experienced
preservation of H3K9ac and partial restoration of H3K4me3 at
the hepcidin promoter (Fig. 4d), and increased Hamp1 mRNA
expression to levels similar to mice receiving control diets
(Fig. 4e). In these experiments, we again observed that mice
receiving PB alone experienced an increase in Hamp1 gene
expression compared with untreated controls and ID + PB mice,
indicating some residual suppression caused by ID in this group.
In ID mice, PB rescued Hamp1 expression but did not
significantly alter bone marrow Fam132b (Fig. 4e). Bmp6 and
Id1 expression were unchanged between ID and ID + PB
conditions, while Smad7 expression was suppressed between
control and ID mice receiving either vehicle or PB (Fig. 4e;
Supplementary Fig. 3i). PB given for this longer time course
caused marginal weight loss in mice (Supplementary Fig. 3j),
perhaps reflecting limited tolerability of this pan-HDAC inhibitor
at high doses32. This course of PB decreased platelets and
marginally decreased Hb (Supplementary Fig. 3k, l), and was
also associated with diminished numbers of intermediate
erythroblasts compared with PB untreated mice (although ID
itself had no effect on erythroblast populations) (Fig. 4f).
However, as presented above, Fam132b (produced by
intermediate erythroblasts) is unnecessary for ID-mediated
hepcidin suppression. Although PB reduced spleen size in control
and ID mice (Supplementary Fig. 4m), splenic Fam132b
expression was not significantly increased in iron-deficient mice
nor was it affected by PB treatment (Supplementary Fig. 3n).
Mice receiving PB on ID diets have lower liver iron than mice
receiving PB alone (Supplementary Fig. 3o). Spleen iron
content was reduced in ID mice, and raised in PB + ID mice
compared with ID alone (Supplementary Fig. 3o), suggesting a
physiologic effect from increased hepcidin; this effect was not
seen when comparing Epo + PB vs Epo alone (Supplementary
Fig. 3h). Together the data indicate that rescue of Epo-mediated
or ID-mediated suppression of hepcidin by PB is unlikely to be
due to effects of PB on either erythroferrone expression or the
liver Bmp pathway, respectively.
HDAC inhibition raises hepcidin in disease models. Next, we
evaluated the ability of PB to raise hepcidin in two disease models
of iron overload—HFE hemochromatosis and β-thalassemia.
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HFE-linked hemochromatosis is an autosomal recessive
condition mediated by inappropriate hepcidin suppression
leading to excess iron absorption in the absence of increased
erythropoietic demand. The Hfe−/− mouse model recapitulates
the human phenotype of hepatic iron overload with relatively low
hepcidin levels33. Treatment of Hfe−/− mice with PB (20 mg/kg
for 3 days) increased hepatic Hamp1 mRNA levels without
changing Bmp6 or Id1 mRNA (Fig. 5a), although PB raised
transferrin saturation, perhaps reflecting PB-induced suppression
of erythropoiesis and decreased uptake of iron by the bone
marrow.
The HbbTh3+/− (Th3/+) mouse model of β-thalassemia
intermedia exhibits ineffective erythropoiesis with anemia,
elevated Epo, splenomegaly, iron loading, and relative hepcidin
suppression16, 34. Th3/+ mice receiving PB 5mg/kg/d for 7 days
had higher serum hepcidin compared with vehicle, and produced
a reduction in serum iron and transferrin saturation (Fig. 5b),
indicating increased hepcidin levels were exerting a physiologic
effect on iron homeostasis. However, in these experiments PB
increased liver iron in Th3/+ mice, which might be explained by
suppression of erythropoiesis and hence increased hepatocyte
iron uptake. PB treatment was accompanied by a reduction in
mean Hb concentration from 8.6 to 7.5 g/dl and reduced
splenomegaly, and at this dose did not induce weight
loss (Supplementary Fig. 4a–c). Flow cytometry of spleens from
Th3/+ mice treated with PB compared with vehicle showed
similar proportions of intermediate erythroblasts potentially
producing erythroferrone (gate III in analysis in Supplementary
Fig. 4d), although proportions in other gates are altered35.
Histone deacetylase inhibition raises HAMP mRNA in vitro.
The above data suggest that HDAC inhibition affects hepcidin
expression at least in part via direct effects on histone acetylation
at the Hamp1 locus, rather than through indirect effects on iron
and/or erythroferrone. To test this idea, we assayed for a direct
effect of HDAC inhibition on hepatic hepcidin expression in
isolated liver cells. We took advantage of BMPs as ligands for
the canonical signaling pathway that regulates homeostatic
hepcidin expression. In the first model, we deployed precision cut
DM
SO
RG
FP
96
6
PB
20 kDa
15 kDa
40 kDaActin 42 kDa
H3K9ac 17 kDa
0 nM 2 nM 6 nM 18 nM
0
20
40
60
80
BMP6 dose
DMSO
PB 10nMP<0.005 for BMP6 dose
P<0.05 for PB dose
0 ng/mL 10 ng/mL 50 ng/mL
0
2
4
6
8
10
BMP9 dose
PB 0 nM
PB 10 nM
PB 100 nM
P<0.0005 for BMP9 dose
P<0.0005 for PB dose
H
D
AC
1
H
D
AC
2
H
D
AC
3
H
D
AC
4
H
D
AC
5
H
D
AC
6
H
D
AC
7
H
D
AC
8
H
D
AC
9
H
D
AC
10
H
D
AC
11
–2
–1
0
1
2
3
Sc
re
en
 z
-
sc
o
re
Threshold=+1.75
Threshold=–1.75
0.00
0.05
0.10
0.15 NS
0.0000
0.0002
0.0004
0.0006 NS
Co
ntr
ol
Ro
mi
de
ps
in
PC
I34
05
1
RG
FP
96
6
Tu
ba
cin
LM
K2
35
Ta
sin
qu
om
od
0.0000
0.0002
0.0004
0.0006
0.0008
0.0010
*
0.000
0.002
0.004
0.006
0.008
NS
Co
ntr
ol PB
Co
ntr
ol PB
Co
ntr
ol PB
Co
ntr
ol PB
0.0000
0.0005
0.0010
0.0015
0.0020
0.0025 *
Sc
ram
ble
HD
AC
3
Sc
ram
ble
HD
AC
10
0.00
0.01
0.02
0.03 **
0.00
0.01
0.02
0.03 NS
Co
ntr
ol
Ro
mi
de
ps
in
PC
I34
05
1
RG
FP
96
6
Tu
ba
cin
LM
K2
35
Ta
sin
qu
om
od
0.0
0.5
1.0
1.5
2.0
H
am
p1
 
m
R
N
A 
(vs
 H
pr
t)
fo
ld
ch
an
ge
 o
ve
r b
as
el
in
e
H
AM
P 
m
R
N
A 
(vs
 G
AP
DH
)
fo
ld
ch
an
ge
 o
ve
r c
on
tro
l
H
uh
7 
H
AM
P 
m
R
N
A
(vs
 G
AP
DH
)
H
uh
7I
d1
 
m
R
N
A 
(vs
 G
AP
DH
)
H
uh
7 
SM
AD
7
m
R
N
A 
(vs
 
G
AP
DH
)
H
uh
7 
At
oh
8 
m
R
N
A
(vs
 G
AP
DH
)
2way ANOVA:2way ANOVA:
H
uh
7 
H
AM
P 
m
R
N
A
(vs
 G
AP
DH
)
H
uh
7 
ID
1 
m
R
N
A
(vs
 G
AP
DH
)
ANOVA P=0.005 ANOVA NS
H
uh
7 
H
AM
P 
m
R
N
A
(vs
 G
AP
DH
)
H
uh
7 
H
AM
P 
m
R
N
A
(vs
 G
AP
DH
)
a b c
d e
f g
Fig. 6 In vitro effects of PB on HAMP expression in liver-derived cells. a Effect of Panobinostat 10 and 100 nM on BMP9- (0, 10, and 50 ng/ml)
induced Hamp1 expression (relative to Hprt) in mouse precision cut liver slices. Data are normalized to baseline (untreated cells). N= 3 separate
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mouse liver slices (PCLS) in vitro, in which liver cellular
architecture is preserved36 but effects of systemic iron status and
erythropoiesis are eliminated. PCLSs were treated with increasing
doses of PB and human BMP9, which we found to best increase
Hamp1 and Id1 mRNA expression in this model (Supplementary
Fig. 5a). BMP9 increased Hamp1 mRNA and PB enhanced this
effect on Hamp1 expression (Fig. 6a). Next, we used the Huh7
human hepatoma-derived cell line to evaluate the effects of PB on
hepatocytes alone in culture. PB treatment of hepatocyte-derived
Huh7 hepatoma cells increased HAMP expression at baseline and
also potentiated the increase of HAMP produced by exogenous
recombinant BMP6 (Fig. 6b, c; Supplementary Fig. 5b). These
effects of PB on HAMP expression were likely independent of
changes in BMP signaling, because PB did not alter baseline
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expression of ID1, SMAD7, and ATOH8 (Fig. 6c), and did not
potentiate the expression of these genes by BMP6 (Supplementary
Fig. 5b). These data indicate that HDAC inhibition enhances
hepatocyte hepcidin expression independently of iron status
and other hepatic and non-hepatic cell types and organs, and
independently of BMP signaling.
Screens implicate HDAC3/NCOR1 in hepcidin regulation.
We used Huh7 cells to investigate the specific HDAC(s) involved
in hepcidin regulation. First, we treated cells with a panel of
inhibitors that possess relative specificity for different HDACs.
We deployed inhibitors against HDAC1/2 (Romidepsin), HDAC3
(RGFP966), HDAC4/5 (LMK235), HDAC4 (Tasinquimod),
HDAC6 (Tubacin), and HDAC8 (PCI-34051). RGFP966 (50 µM)
but no other inhibitor enhanced HAMP expression, with no effect
on ID1 mRNA (Fig. 6d) or expression of other BMP-regulated
genes (Supplementary Fig. 5c). Treatment of Huh7 cells with
either RGFP966 or PB increased H3K9ac in whole-cell lysates
(Fig. 6e). Next, we obtained data from a previously published
RNAi screen evaluating effects on hepcidin promoter activity
of knockdown of 19,599 genes37, and plotted effects from
knockdown of HDAC1-11. In this screen, only knockdown of
HDAC3 and HDAC10 produced an increase in HAMP promoter
activity (above the threshold of a z-score> 1.75 as defined by the
authors) (Fig 6f). However, subsequent validation experiments
confirmed that knockdown of HDAC3 upregulated HAMP
expression, whereas knockdown of HDAC10 had no effect on
HAMP (Fig. 6g; Supplementary Fig. 5d).
The effect of RGFP966 on hepcidin expression was also
observed at a lower dose of 10 µM, at which concentration it
does not inhibit any other HDAC other than HDAC338.
RGFP966 (10 µM) increased HAMP expression both at
baseline and enhanced the effect of BMP6 on hepcidin
expression; as a positive control, RGFP966 also increased baseline
expression of the recognized HDAC3 target gene CDKN1A
(Fig. 7a)39. In complementary short interfering RNA (siRNA)
experiments, we confirmed that HDAC3 knockdown also
increased both HAMP and CDKN1A expression (Fig. 7b), but
did not alter expression of BMP target genes ID1 and SMAD7
(Supplementary Fig. 6a).
We then tested effects of HDAC3 overexpression in Huh7 cells
on hepcidin expression. Cells were transfected with plasmid
encoding HDAC3 under a CMV promoter and harvested after 48
h, at which point ~30% of cells were transfected in parallel
experiments with GFP-tagged plasmids, and FLAG-tagged
HDAC3 protein was readily detectable by western blot (Fig. 7c).
Compared with empty vector controls, cells overexpressing
HDAC3 exhibited reduced HAMP expression (Fig. 7c) but not
CDKN1A or BMP-regulated genes (Supplementary Fig. 6b).
HDAC3 forms a complex with co-repressors, NCOR1
and NCOR2 (SMRT), which are required for deacetylase
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activity40, 41. RGFP966 inhibits HDAC3 and NCOR142, raising
the possibility that NCOR1 is also involved in hepcidin
expression. Knockdown of either NCOR1 or HDAC3 individually
raised HAMP expression in Huh7 cells (Fig. 7d). However,
simultaneous knockdown of NCOR1 together with HDAC3
augmented the increase in HAMP expression above that seen
with knockdown of either of these genes alone (Fig. 7d;
Supplementary Fig. 6c). These data suggest that hepcidin
expression is regulated by a complex comprising HDAC3
and NCOR1. We observed no increase in CDKN1A
expression in knockdown of NCOR1 alone, but enhanced
expression above HDAC3 knockdown alone when double
knockdown was performed (Fig. 7d). Combined knockdown of
HDAC3 and NCOR1 had no effect on SMAD7 expression
although in these experiments we observed upregulation of ID1
(Supplementary Fig. 6c).
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Fig. 9 Enrichment of HDAC3 at the hepcidin locus and effects of HDAC3 inhibition on genome-wide RNA expression profile. a Six-week-old C57Bl/6 male
mice were administered Epo daily for 3 days 200 IU i.p. or control. ChIP-qPCR for HDAC3 (compared with IgG isotype control) at the hepcidin gene locus,
along with the Cdkn1a locus as a positive control and a negative control genomic region. N= 3, paired t-tests. RNA sequencing of livers from mice treated
with 3 weeks low-iron diet followed by either vehicle or two doses of RGFP966. Three biologic samples (those with the highest quality RNA) were selected
for sequencing from each group. b Smear plot (log fold change vs expression levels), highlighting Hamp and Cdkn1a genes. c Volcano plot (P-value vs log
fold change) highlighting Hamp and Cdkn1a genes. d HDAC3 ChIP-Seq peaks were annotated and compared to differentially expressed genes. Expression of
each HDAC in 6-week-old mice treated with e Epo vs control, and f ID vs control. Significance testing adjusted for multiple comparisons. N= 8 per group,
same mice as experiments presented in Fig. 4
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00500-z
10 NATURE COMMUNICATIONS |8:  403 |DOI: 10.1038/s41467-017-00500-z |www.nature.com/naturecommunications
HDAC3 knockdown counteracts induced HAMP suppression.
We tested how suppressors of hepcidin expression (recombinant
erythroferrone and the ALK2/3 inhibitor LDN193189 (LDN))
interacted with HDAC3 inhibition. We found that relative to
untreated cells, both erythroferrone (Fig. 7e) and LDN (Fig. 7f)
inhibited hepcidin expression, while HDAC3 knockdown
(Supplementary Fig. 6d) increased expression. The combination
of HDAC3 knockdown with either erythroferrone or LDN at 1
nM led to hepcidin expression levels similar to untreated
cells; higher LDN concentrations suppressed hepcidin even in
the presence of HDAC3 knockdown. HDAC3 inhibition
acted independently of effects on other BMP target genes
(Supplementary Fig. 6e). Thus, HDAC3 knockdown counteracts
dose-dependent inhibition by physiologic suppressors.
HDAC3 inhibition partly rescues ID-induced Hamp1
suppression. Next, we studied effects of inhibition of HDAC3
on hepcidin expression in vivo. Mice received an iron-deficient
diet for 3 weeks, followed by two intraperitoneal injections of
RGFP966 20 mg/kg/dose 2 h apart, and were then killed 2 h after
the second dose; this time course was used because of the short
half-life of RGFP966 in vivo38. This regimen induced hepatic
upregulation of the HDAC3-responsive gene, Cdkn1a (Fig. 8a).
This was accompanied by upregulation of Hamp1 mRNA
expression (Fig. 8b). Hepatic Bmp target genes (Id1, Atoh8,
and Smad7, Fig. 8c–e) and Bmp6 expression itself (Fig. 8f)
were not affected by RGFP966 treatment. HDAC3 inhibition
was associated with an increase in liver iron
content (Fig. 8g), although Perls’ stain of liver sections from
control (Supplementary Fig. 7a) and RGFP966-treated mice
(Supplementary Fig. 7b) did not demonstrate detectable liver iron
staining. Increased hepcidin expression was accompanied by
decreased ferroportin protein levels in the liver (Fig. 8g) and
increased spleen iron (Fig. 8i).
HDAC3 binds to the hepcidin gene locus. We sought to
establish whether HDAC3 may directly regulate hepcidin. Using
ChIP-qPCR in mouse liver we measured HDAC3 at the hepcidin
locus (near the transcription start site), using HDAC3 binding to
the CDKN1A gene locus as a positive control. These experiments
demonstrated that HDAC3 is enriched at the hepcidin promoter
(compared to HDAC3 binding at a negative control region) and
compared with an IgG isotype control antibody, and that binding
was similar to HDAC3 at the CDKN1A locus (Fig. 9a). Treatment
of mice with Epo did not significantly alter HDAC3 enrichment
at the hepcidin (or CDKN1A) promoter.
Hepcidin is a key HDAC3 regulated gene in vivo. To establish
the specificity of effect of HDAC3 inhibition on hepcidin
upregulation, we performed RNA sequencing on livers of mice on
a low-iron diet or low-iron diet with RGFP966 as above. Hepcidin
was the third most differentially expressed gene (defined as
log fold change) (Fig. 9b), with the 146th smallest adjusted
P-value (P= 1.16 × 10−8) (Fig. 9c) out of 1464 differentially
expressed genes, supporting the idea that hepcidin is a
key HDAC3 regulated gene in vivo. A complete list of differen-
tially expressed genes is provided in the Supplementary Material,
and validation of top differentially expressed genes (B3galt1,
Igfbp1, Lcn2) is shown in Supplementary Fig. 7d.
Next, we sought to establish whether HDAC3 peaks were more
commonly seen on expressed genes in the liver (as has
been observed in T-cells). We mined and re-analyzed publically
available HDAC3 ChIP-Seq data. After remapping the data on to
the mm10 mouse genome and performing peak calling, the list of
peaks was compared to genes identified by RNA sequencing to be
expressed (defined as expression above 1 count per million for at
least three samples across the two conditions) in the liver in our
experiments. We observed that expressed genes were more likely
to have an HDAC3 peak (defined as a peak called within 5 kb
of the transcription start site): odds ratio 8.3 (95% CI 7.8, 8.83),
P< 10−16, χ2-test, demonstrating that in the liver, HDAC3 binds
to expressed genes. Next, we tested whether effects of RGFP966
on gene expression were associated with HDAC3 binding.
We observed enrichment for genes with an HDAC3 peak
in genes differentially expressed by RGFP966 (odds ratio 1.32
(95% CI 1.18, 1.49), P= 2 × 10−6) (Fig. 9d). These data confirm
that effects of HDAC3 inhibition on gene expression are
more common in genes sited at regions with genomic binding
of HDAC3.
Epo and ID do not alter hepatic HDAC3 expression. Finally,
we measured mRNA expression levels of all HDACs in control
mice vs mice receiving Epo, and control mice vs mice receiving a
2-week low-iron diet. We observed that HDAC3 is expressed in
the liver, although less so than (other Class I HDACs) HDAC1
and 2. Neither Epo nor ID produce a change in HDAC3 (or other
HDAC) transcription (Fig. 9f). Among Class II HDACs, HDAC7
and HDAC9 expression is low.
Discussion
Suppression of hepcidin can be physiologic, facilitating
iron absorption and making recycled iron available for cells in
conditions of ID or stress erythropoiesis, but it can also be
harmful in patients with ineffective erythropoiesis due to genetic
conditions such as thalassemia or congenital dyserythropoietic
anemia, or due to genetic disruption of the hepcidin regulatory
pathways in hereditary hemochromatosis. Gene expression and
suppression are linked with characteristic post-translational
chromatin modifications. Here, we provide evidence that
dynamic changes in hepcidin expression induced by ID
and increased erythropoiesis are directly mediated by hepcidin-
associated chromatin acetylation. We also find that hepcidin is
an HDAC3 regulated gene, and one of genes most differentially
expressed by HDAC3 inhibition.
To gain insight into the mechanisms of hepcidin suppression,
we used two in vivo models: ID induced by a low-iron diet,
and increased erythropoiesis caused by administration of Epo.
Suppression of hepcidin by stimulated erythropoiesis is at least
partly mediated by secretion of erythroferrone from intermediate
erythroblasts. Erythroferrone knockout mice fail to suppress
hepcidin when they undergo stimulated erythropoiesis8, data that
we have recapitulated. An interaction between erythropoiesis and
ID to effect erythroferrone-mediated hepcidin suppression has
been proposed43, and studies evaluating the role of erythroferrone
in ID have been called for44. We found, using erythroferrone
knockout mice, that hepcidin suppression induced by low-iron
diet is erythroferrone-independent, and is associated with
reductions in BMP signaling.
Key histone activation marks include H3K9ac, which enhances
accessibility for transcription factor binding via electrostatic
opening of DNA from chromatin and by acting as docking
sites for proteins involved in transcription including SWI/SNF,
transcription elongation complexes, and HATs, e.g., p30029.
H3K4me3 also enables gene expression by facilitating binding of
factors involved in transcription45.
Our data indicate that for both ID and enhanced
erythropoiesis, suppression of hepcidin expression involves
reversible erasure of histone activation marks at
hepcidin-associated chromatin. We found that mice receiving PB
alone underwent hyperacetylation of the Hamp1 promoter (when
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compared with untreated mice), and increased hepcidin gene
expression. HDAC inhibition in in vivo models of physiologic
and pathologic hepcidin suppression showed a consistent effect
in raising hepcidin levels. Treatment of thalassemic mice with
low-dose PB increased hepcidin levels and reduced serum iron
concentrations, indicating a physiologic effect on cellular iron
export. Hepcidin was also raised by PB in Hfe−/− mice. However,
PB elevated liver iron in the Th3/+ and Hfe−/− animals, limiting
its clinical value. PB also increased serum iron in the Hfe−/−
model. Similar effects were seen with the HDAC3 inhibitor
RGFP966 in iron-deficient mice. While the explanation
for increased liver iron is unclear, it may potentially be due to
suppressed erythropoiesis and therefore reduced iron uptake by
the marrow for heme synthesis. However, PB did not change
erythroid maturation and only slightly reduced bone marrow
erythroferrone expression in mice treated with Epo. Likewise, PB
and RGFP966 did not appear to affect BMP signaling given BMP
target gene expression was unchanged. Thus, effects of HDAC
inhibition on hepcidin elevation appear direct, and physiologic,
with reductions in ferroportin and increased spleen iron, while
elevations in liver iron remain difficult to explain and limit
potential clinical application at this stage.
A direct effect of HDAC inhibition on hepcidin expression was
supported by in vitro data indicating that pan-specific HDAC
inhibitors enhanced hepcidin expression without concomitant
increases in other BMP target genes in both primary
and immortalized hepatocytes. These findings extend those of a
previous screen of 10,169 small molecules that identified a
pan-HDAC (vorinostat) as one of 16 compounds capable of
upregulating hepcidin expression and reporter activity24, and
recent data showing HDAC inhibitors can elevate hepatic HAMP
expression in vitro25. Collectively, these data indicate that HDAC
inhibition directly affects hepcidin expression.
We hypothesized that a specific HDAC might be responsible
for control of hepcidin. We combined a panel of inhibitors with
relative specificity for different HDACs and a gene-specific RNAi
approach to investigate which HDAC(s) contribute to hepcidin
regulation. Both of these approaches independently found
that HDAC3 inhibition increased hepcidin expression in vitro.
Furthermore, HDAC3 knockdown counteracted erythroferrone
and LDN193189 (BMP signaling inhibitor)-mediated suppression
of hepcidin, and conversely, HDAC3 overexpression decreased
hepcidin expression. HDAC3 inhibition also selectively
increased hepcidin expression in vivo in iron-deficient mice
without altering expression of Bmp6 or Bmp target
genes. HDAC3 is essential to the regulation of a range of hepatic
processes, including gluconeogenesis46 and lipid metabolism47.
Our ChIP-qPCR data confirmed that HDAC3 is enriched at the
hepcidin locus. RNA sequencing demonstrated that hepcidin is
one of the genes most differentially expressed in livers of mice
treated with an HDAC3 inhibitor. Analysis of RNA-Seq and
HDAC3 ChIP-Seq confirmed that HDAC3 is enriched at genes
differentially expressed by RGFP966.
HDAC3 binds to promoter regions of active genes and regulate
their acetylation and hence expression levels48. The histone
deacetylation function of HDAC3 is contingent on its interaction
with at least one of two co-repressors, NCOR1 and SMRT
(NCOR2)41. Effects of HDAC3 on histone acetylation and hepatic
metabolic processes have been identified to be both deacetylase
dependent (likely contingent on NCOR1) and deacetylase
independent49. Our study extends the functions associated with
HDAC3 and its cofactor NCOR1 to include regulation of
iron homeostasis via hepcidin. While inhibition of HDAC3
raises hepcidin expression in vitro and elevates hepcidin
expression in iron-deficient mice, erythropoiesis and ID do not
appear to change hepatic HDAC3 transcription, and
erythropoiesis does not affect localization of HDAC3 to the
hepcidin locus. Thus, we hypothesize that HDAC3 is
necessary but not sufficient in itself to effect changes in hepcidin
transcription. Instead, changes to HDAC3 function relating to
interaction with cofactors in its complex (e.g., NCOR1)
may mediate effects on histone acetylation and gene expression
due to erythropoiesis and ID. Although we have not yet been
able to demonstrate clinical benefit, targeting of HDAC3 or
cofactors in the future may have therapeutic potential.
Conversely, HDAC3 inhibition has been proposed for treatment
of neurocognitive disorders38 and cancer; our data indicate
such treatments may also have implications of iron metabolism.
Interestingly, hepatic HDAC3-NCOR1 is known to regulate
circadian processes;50 it would be of interest to discover
whether the well-characterized diurnal variation in serum iron
and hepcidin51 may also be mediated by this complex.
Expression of the master iron regulatory hormone hepcidin is
regulated by histone acetylation state at its locus. Suppression of
hepcidin by either ID or enhanced erythropoiesis converge by
altering epigenetic marks on promoter-associated chromatin.
Hepcidin suppression is pathological in the common disorders
of hereditary hemochromatosis and thalassemia and relieving
histone deacetylation in models of these disorders rescues
hepcidin expression although we were not able to confirm
functional benefits on liver iron overload in these systems.
HDAC3 binds to the hepcidin promoter, and the
HDAC3–NCOR1 complex is likely responsible at least in part for
regulation of hepcidin. These new insights indicate a role for
epigenetic regulation in systemic iron homeostasis.
Methods
Mice. Wild-type male C57Bl/6 mice were purchased from Harlan Laboratories,
UK. Animals were housed in individually ventilated cages in the Department of
Biomedical Services, University of Oxford, and provided access to normal chow
(188 ppm, SDS Dietex Services 801161, other than for dietary iron manipulations)
and water ad libitum. For Epo treatments, mice were injected intraperitoneally with
200 IU recombinant human Epo (AbD Serotec) in water daily. For iron-deficient
diet experiments, mice were administered a 2–6 ppm iron diet (Harlan UK,
TD.99397) or a control 200 ppm iron diet (Harlan TD.07801). Embryos from
Fam132b+/− mice on a mixed Sv129/C57BL/6 background were obtained from
the Mutant Mouse Regional Resource Center (MMRRC) at UC Davis (strain
B6;129S5-Fam132btm1Lex/Mmucd, ID MMRRC:032289-UCD) and rederived.
Heterozygote pairs were mated to generate homozygous animals from which
knockout and wild-type colonies were maintained. Hfe−/− mice on C57Bl/6
background52 were bred at the Instituto de Biologia Molecular e Celular animal
facility. Animals were housed in a temperature and light-controlled environment,
with free access to standard rodent chow (Harlan 2018S, containing 200 ppm iron)
and water. PB was administered to male mice aged 15 weeks. Animals were cared
for according to local ethics regulations. In Oxford, animals experiments were
undertaken under a Home Office Project License 40/3636. In Portugal, animal
experiments were approved under Federation of European Laboratory Animal
Science Associations criteria for the care and handling of laboratory animals.
Experimental procedures were approved by the Instituto de Biologia Molecular
e Celular Animal Ethics Committee. Hbbth3/+ (th3/+) female mice (C57Bl/6
background) were as follows:
Cell culture. HUH7 cells (an immortalized human hepatoma cell line53) were
cultured in Dulbecco’s Minimum Essential Medium supplemented with 10% fetal
calf serum, 1% Glutamine, and 1% Penicillin/ streptomycin, and were plated and
treated as described in the text. Huh7 cells were a kind gift of Prof Persephone
Borrow, University of Oxford.
Precision cut liver slices. PCLS were cultured up to 24 h in 12-well plates with
William E + Glutamax (Gibco, Grand Island, New York, USA), supplemented
with 14 mM D-Glucose (Merck, Darmstadt, Germany) and 50 µg/ml gentamicin
(Gibco, Grand Island, New York, USA) at 37 °C in an O2/CO2 incubator
(MCO-18M, Sanyo, USA), which was continuously shaken at a speed of 90 rpm
and saturated with 80% O2 and 5% CO2. PCLS were treated as described in the text.
Experiments using mice as a source for precision cut liver slices were approved by
the Animal Ethical Committee of the University of Groningen, Netherlands36.
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Drug treatments. PB (LC Laboratories, Woburn Massachusetts, USA) was
reconstituted in DMSO and, for mouse experiments was diluted in vehicle
(H2O with tween 5%, PEG 5%). Specific HDAC inhibitors were reconstituted in
DMSO: Romidepsin (Selleck), RGFP966 (Selleck), LMK235 (Selleck), Tasinquimod
(Selleck), Tubacin (Sigma), PCI-34051 (Selleck). Recombinant Human
BMP6 (R&D systems) and Recombinant Human BMP9 (R&D systems) were
reconstituted in sterile 4 mM HCl containing 0.1% bovine serum albumin.
LDN193189 (Sigma) was diluted in H2O.
RNA extraction. Murine tissue explants were stored in RNA later (Ambion) and
homogenized by TissueRuptor (Qiagen). RNA was extracted using the RNeasy
Mini or RNeasy Plus (when genomic DNA depletion was required) kits (Qiagen)
following the manufacturer’s protocols. RNA was reverse transcribed using the
High-Capacity RNA-to-cDNA kit (Applied Biosystems).
Quantitative real-time PCR. Gene expression was quantified using quantitative
real-time PCR using inventoried TaqMan Gene Expression assays (Supplementary
Table 1) and TaqMan Gene Expression Master Mix (Applied Biosystems).
Changes in gene expression relative to endogenous controls (Hprt1 for mouse,
GAPDH for human) were calculated using the 2−ΔCT method. Experimental
conditions (Epo, ID, PB) did not produce any systematic alteration in threshold
cycle (Ct) values for these housekeeping genes.
Chromatin immunoprecipitation assays. ChIP was performed on either fresh
or snap frozen whole-liver samples, or on Huh7 cells confluent in a T75 flask.
Tissue was either processed immediately after harvest, or snap frozen in Liquid N2,
and then subsequently thawed on ice. Huh7 cells were washed with PBS,
dissociated with trypsin, and the pellet washed and fixed. For chromatin marks
and RNA pol ii, samples were minced and fixed in 1% formaldehyde for 10 min
followed by quenching with glycine, washing, douncing (20 strokes) and lysing in
lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris). Samples were snap frozen again,
then thawed on ice and sonicated (Bioruptor, Diagenode) on high for 10–15 cycles.
Aliquots of cells were diluted in dilution buffer (0.01% SDS, 1.1% TritonX-100, 1.2
mM EDTA, 16.7 mM Tris-HCl, 167 mM NaCl) and pre-cleared using mixed
Protein A/G beads. Cells were then rotated for 16 h at 4 °C with the relevant
antibody. Antibodies bound to chromatin were incubated with Protein A/G beads
at 4 degrees for 5 h, and were then washed five times with RIPA buffer (50 mM
Hepes-KOH, 500 mM LiCl, 1 mM EDTA, 1% NP-40, 0.7% Na-Deoxycholate).
Chromatin was then eluted from the beads by heating at 65 °C in an elution buffer
(50 mM Tris-HCl, 10 mM EDTA, 1% SDS) for 30 min, after which DNA was
decrosslinked overnight. For HDAC3, liver samples were crosslinked using
Crosslink gold (Diagenode) and ChIP performed using the Transcription Factor
ChIP kit (Diagenode). Antibodies were H3k9ac Abcam ab10812 0.5 µg per IP;
H3k4me3 Diagenode C15410003 1 µg per IP; RNA pol ii Diagenode C15200004 1
µg per IP; H3K27me3 Diagenode C15410195 1 µg per IP; HDAC3 Abcam ab7030
4 µL per IP. ChIP for HDAC3 was performed using the IDeal ChIP-Seq kit for
transcription factors (Diagenode). qPCR using primers to amplify sections of
genomic DNA of interest (Fig. 2a; Supplementary Fig. 2) and Fast SYBR Green
Master Mix (Applied Biosystems) to measure relative enrichment of sample relative
to input was performed (%input). A genomic region known to be enriched for the
relevant mark was run as a positive control (e.g., the promoter of Hprt for H3K9ac
and H3K4me3, Pax2 for H3K27me3, Ckdn1a for HDAC3) and a negative control
primer in a gene desert was also assessed to exclude non-specific binding. For
H3K9ac and H3K4me3, results in regions of interest were normalized to positive
controls to improve comparability between replicates (%input/ %input). Primer
sequences are presented in Supplementary Table 2.
RNA sequencing. Mouse liver RNA was extracted as above. RNA was converted to
cDNA using Smartseq2 reagents, and libraries were prepared using the Nextera XT
library preparation kit (Illumina). Sequencing was performed on a NextSeq using
the FC-404-2002 NextSeq 500/550 High Output Kit v2 (150 cycles) 400 million
reads. Following QC analysis with the fastQC package (http://www.bioinformatics.
babraham.ac.uk/projects/fastqc), reads were aligned using STAR1 against the
mouse genome assembly (GRCm38 (mm10) UCSC transcripts). Gene expression
levels were quantified as read counts using the featureCounts function2 from the
Subread package3 with default parameters. The read counts were used for the
identification of global differential gene expression between specified populations
using the edgeR package4. RPKM values were also generated using the edgeR
package. Genes were considered differentially expressed between populations if
they had an adjusted P-value (false discovery rate, FDR) of less than 0.05. The gene
ontology analysis was performed using the goseq R package accounting for gene
length bias5 and GO categories were considered significantly enriched if they had
an FDR< 0.05. Venn diagrams were created using the R package VennDiagram.
Re-analysis of publically available HDAC3 ChIP-Seq. We obtained publically
available data from a previously reported liver HDAC3 ChIP-Seq experiment
the Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSM1659699). Reads were then aligned using Bowtie2 to mouse genome build
mm10 followed by peak calling using MACS2.
Hepcidin ELISA, transferrin saturation, and serum iron—mouse. Hepcidin
ELISAs (Intrinsic Life Sciences) were performed on 12 µL mouse serum. Serum
iron and total iron binding capacity were measured in a Cobas C8000 analyzer
(Roche Diagnostics, Mannheim, Germany) at Centro Hospitalar do Porto.
Tissue non-heme iron measurement. Snap frozen liver or spleen samples
were thawed and then dried at 95 °C for 3 h, followed tissue by digestion with
10% trichloroacetic acid/30% hydrochloric acid for 20 h at 65 °C. Acid
supernatants were then mixed with chromogen reagent containing 0.1%(w/v)
bathophenoldisulphonic acid (BPS, 146617, Sigma)/0.8% thioglycolic acid
(88652, Sigma). Non-heme iron was colorimetrically measured (OD 535 nm)
against a freshly constituted standard curve generated from ferric ammonium
citrate (F5879, Sigma).
Flow cytometry. Spleens were collected in PBS + 10% FCS and cells passed
through a 70 µm filter and washed. Cells were stained with Anti-Ter119 (PE, BD
Biosciences 553673), Anti-CD44 (APC, BD Biosciences 559250), and Anti-CD71
(FITC, eBiosciences, 11-0711-82), and analyzed using Cyan-ADP (Beckman
Coulter) with FlowJo v10.1. Cells were gated according to FSC-H and SSC-H,
followed by identification of singlets by FSC-H vs Pulse Width. Live cells were
defined as DAPI negative. Within live cells the expression CD71 against Ter119
was used to describe the differentiation of erythroid cells. For the thalassemia
experiment, live cells were gated according to FSC-H and SSC-H. Erythroid lineage
cells were gated as Ter119 positive and then segregated into different stages of
development by CD44 against FSC-H.
Western blots. Cells or snap frozen liver were lysed in RIPA buffer with
protease inhibitor. Lysates were denatured at 95 °C, and separated on a 10% SDS
polyacrylamide gel (Bio-Rad 456-1036EDU). Protein was transferred to a
nitrocellulose membrane, then blocked with milk/TBS for 1 h. Antibodies used
were anti-H3K9ac (Abcam ab10812 1:500), anti-SLC40A1 (Novus, NBP1-21502
1:1000), anti-FLAG (Sigma A592 1:5000), anti-Actin (Sigma A3854 1:5000), and
donkey-anti-goat IgG (Santa Cruz sc-2020 1:5000). Uncropped western blot gels
for Figs. 6e, 8h are shown in Supplementary Fig. 8.
siRNA knockdown experiments. Huh7 cells were plated at 50% confluency; after
8 h they were transfected with siRNA (siGenome Smartpool, Dharmacon; Silencer
select, Ambion) using Lipofectamine RNAiMAX (Thermofisher), Opti-MEM
(Thermofisher) and antibiotic-free media. For experiments involving both single
and double knockdown, the total amount of siRNA added was the same and
maintained by using scramble together with single knockdowns. Cells were
harvested after a further 48 h. Knockdown efficiency was assessed by measuring
residual gene expression relative to scramble by RT-PCR.
Validation siRNA experiments following siRNA screen. For RNAi of HDAC3
and HDAC10, we reverse transfected Huh7 in 24-well plates, using 50 pmol of
siRNA pool (siGenome, Dhamacon), 1.5 µl Dharmafect1 (Dharmacon) and seeded
13 × 104 cells. Cells were cultured for 72 h prior to harvesting of total RNA. RNA
extraction was performed using RNeasy kit (Qiagen). RNA was reverse transcribed
using RevertAid H Minus M-MuLV reverse transcriptase (Fermentas) according
to the manufacturer’s protocol. Real-time PCR (qPCR) was carried out on the
StepOnePlusTM Real-Time PCR System (Applied Biosystems) using SYBR Green
PCR Master Mix (Applied Biosystems) and primers shown in Supplementary
Table 1.
Hepcidin ELISA, transferrin saturation, and serum iron—mouse. Hepcidin
ELISAs (Intrinsic Life Sciences) were performed on mouse serum diluted 1:20.
Serum iron, transferrin, and total iron binding capacity were measured in a Cobas
C8000 analyzer (Roche Diagnostics, Mannheim, Germany).
HDAC3 overexpression. Huh7 cells at 70–80% confluency were transfected in
antibiotic-free media with pCMV6 entry vector containing either HDAC3 (DDK
tagged, Origene, RC200605) or no gene (empty vector control, Origene, PS100001)
using Lipofectamine LTX Plus (Thermo fisher Scientific).
Expression of recombinant mouse erythroferrone. Mouse Fam132b DNA
(NM_173395) was cloned into the pENTR4.LP shuttle vector54 containing tandem
tetracycline operators55 after replacing its native secretion signal sequence with the
one from mouse IgG, inserting a Kozak sequence and C-terminal addition of a G4S
linker, and a C-tag via KpnI and EcoRI sites and purified (Maxiprep, Qiagen). The
plasmid was transiently transfected in the Expi-CHO system (Gibco, Thermo-
scientific). Supernatants were harvested 13 days post transfection and the mouse
ERFE protein was affinity purified via CaptureSelect C-tag affinity matrix (Life
Technologies, Thermo Fisher Scientific) using 2 M MgCl2, 20 mM Tris, pH 7.0.
Statistics. Statistical analyses were performed using Prism 6 (GraphPad Software).
Where differences between treatment groups were experimentally hypothesized,
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means were compared using t-tests. Multiple groupwise comparisons where
differences between individual groups were not hypothesis driven were made by
ANOVA. Changes in gene expression in paired untreated/ treated samples
from cell culture experiments were assessed using paired t-tests, and paired ratio
t-tests if baseline variation was high between experiments. Significance was defined
as P< 0.05.
Data availability. RNA sequencing data have been deposited in NCBI’s Gene
Expression Omnibus and under accession code GSE100608. Other data are
available from the authors upon reasonable request.
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